Related Experiment Video
Updated: Jun 3, 2026
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
A small molecule AMPK activator protects the heart against ischemia-reperfusion injury
Agnes S Kim1, Edward J Miller, Tracy M Wright
1Yale University School of Medicine, Section of Cardiovascular Medicine, 333 Cedar Street, New Haven, CT 06510, USA.
Abstract:
AMP-activated protein kinase (AMPK) is a stress signaling enzyme that orchestrates the regulation of energy-generating and -consuming pathways. Intrinsic AMPK activation protects the heart against ischemic injury and apoptosis, but whether pharmacologic AMPK stimulation mitigates ischemia-reperfusion damage is unknown. The aims of this study were to determine whether direct stimulation of AMPK using a small molecule activator, A-769662, attenuates myocardial ischemia-reperfusion injury and to examine its cardioprotective mechanisms. Isolated mouse hearts pre-treated with A-769662 had better recovery of left ventricular contractile function (55% vs. 29% of baseline rate-pressure product; p=0.03) and less myocardial necrosis (56% reduction in infarct size; p<0.01) during post-ischemic reperfusion compared to control hearts. Pre-treatment with A-769662 in vivo attenuated infarct size in C57Bl/6 mice undergoing left coronary artery occlusion and reperfusion compared to vehicle (36% vs. 18%, p=0.025). Mouse hearts with genetically inactivated AMPK were not protected by A-769662, indicating the specificity of this compound. Pre-treatment with A-769662 increased the phosphorylation and inactivation of eukaryotic elongation factor 2 (eEF2), preserved energy charge during ischemia, delayed the development of ischemic contracture, and reduced myocardial apoptosis and necrosis. A-769662 also augmented endothelial nitric oxide synthase (eNOS) activation during ischemia, which partially attenuated myocardial stunning, but did not prevent necrosis. AMPK is a therapeutic target that can be stimulated by a direct-acting small molecule in order to prevent injury during ischemia-reperfusion. The use of AMPK activators may represent a novel strategy to protect the heart and other solid organs against ischemia.
Insights
Pharmacologic stimulation of AMP-activated protein kinase (AMPK) with A-769662 protects the heart from ischemia-reperfusion injury. This AMPK activation preserves cardiac function and reduces infarct size, offering a novel cardioprotective strategy.
Area of Science:
- Cardiovascular Biology
- Metabolic Signaling
- Pharmacology
Background:
- AMP-activated protein kinase (AMPK) regulates cellular energy pathways and offers intrinsic cardioprotection against ischemic injury.
- The potential of pharmacologic AMPK activation to mitigate myocardial ischemia-reperfusion (I/R) damage remains largely unexplored.
Purpose of the Study:
- To investigate whether direct AMPK stimulation using the small molecule activator A-769662 can attenuate myocardial I/R injury.
- To elucidate the underlying cardioprotective mechanisms of A-769662-mediated AMPK activation.
Main Methods:
- Isolated mouse hearts and in vivo mouse models underwent pre-treatment with A-769662 or vehicle before inducing I/R.
- Cardiac function, infarct size, myocardial apoptosis, necrosis, and specific molecular markers (e.g., eEF2 phosphorylation, eNOS activation) were assessed.
- Studies utilized genetically modified mice with inactivated AMPK to confirm compound specificity.
Main Results:
- A-769662 pre-treatment significantly improved recovery of left ventricular contractile function and reduced infarct size in isolated hearts and in vivo models.
- Hearts treated with A-769662 exhibited preserved energy charge, delayed ischemic contracture, reduced apoptosis/necrosis, and augmented eNOS activation.
- Protection was dependent on AMPK activity, as genetically inactivated AMPK hearts showed no benefit from A-769662.
Conclusions:
- Direct pharmacologic activation of AMPK with A-769662 confers significant cardioprotection against I/R injury.
- AMPK activation preserves cardiac function by maintaining energy charge, reducing cell death, and modulating key signaling pathways like eEF2 and eNOS.
- AMPK activators represent a promising therapeutic strategy for protecting the heart and other organs from I/R damage.
